QIAGEN Launches Innovative Products for Gene Expression Analysis
QuantiFast® Multiplex PCR Kit combines multiplex technology with fast cycling
Venlo, The Netherlands - June 19, 2008 - RNA purification and messenger RNA (mRNA) quantification can be done more quickly and with less sample material using three new products introduced by QIAGEN this month. The RNeasy® Plus 96 Kit is the only 96-well RNA purification kit that does not require time-consuming DNase digestion, even for applications particularly sensitive to minute amounts of DNA. The QuantiFast® Multiplex PCR Kit is the first to integrate multiplex technology with fast-cycling capabilities, making real-time PCR and two-step RT-PCR up to two times faster to complete. In another first, the AllPrep® DNA/RNA 96 Kit is the only kit that can simultaneously purify genomic DNA and total RNA from the same sample using a 96-well format, saving time by as much as 50 percent.
Gene expression and function analyses are critical to understanding the role of various genes in the development of serious diseases such as cancer. The two most important steps for an accurate analysis of gene expression are RNA purification and quantification of mRNA.
"As researchers are facing intense competition to publish and win funding - pushing them to work faster, they are seeking solutions that not only offer high sensitivity and reproducibility, but also significant time savings and conservation of precious samples," said Dr. Annette Tietze, Global Product Manager at QIAGEN. "That is why technologies that allow simultaneous purification of DNA and RNA, simple workflows, standardized procedures and ready-to-use kits are in demand. QIAGEN's new products for RNA purification and mRNA quantification meet these needs."
The QuantiFast Multiplex PCR Kit is the first product on the market that uses real-time PCR to rapidly analyze up to four targets at once by integrating multiplex technology with a fast-cycling capability. The result is significant reduction of PCR run times of up to 50 percent and, as well as the ability to save precious sample material. In addition, the multiplex technology allows higher reliability in results by simultaneously detecting an endogenous control gene in the sample of interest. The kit also offers a specifically developed master mix and a universal protocol that can be used on all available real-time cyclers - both standard and fast - thus enabling flexible application and eliminating the need for tedious optimization of reaction and cycling conditions.
The AllPrep DNA/RNA 96 Kit is the first to allow simultaneous high-throughput purification of genomic DNA and total RNA using the same sample and a 96-well format. The kit cuts processing time by up to 50 percent and is suitable for purification of high-quality DNA and RNA from cultured cells and easy-to-lyse tissues. Since there is no need to divide the sample for separate purification procedures, higher yields of DNA and RNA can be achieved. The purified DNA and RNA are eluted separately and are ready-to-use for any downstream application.
The RNeasy Plus 96 Kit saves time in high-throughput RNA purification by enabling direct removal of genomic DNA and eliminating the normally necessary step of DNase digestion. This allows 96 samples to be processed in less than 50 minutes. Learn more at http://www.qiagen.com/.
QuantiFast Multiplex PCR Kits, the AllPrep DNA/RNA 96 Kit and the RNeasy Plus 96 Kit are intended for research use. No claim or representation is intended to provide information for the diagnosis, prevention or treatment of disease.
QIAGEN NV, headquartered in the Netherlands, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue, and assays make these isolated molecules visible to facilitate such vital activities as biological research and detection of disease. QIAGEN has developed and markets more than 500 products as well as instruments that make their use more efficient and accurate. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide, including the only FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs more than 2,600 people in over 30 locations worldwide.